R
Revolution Medicines
Targeted therapies for previously undruggable RAS-addicted cancers
At a glance
- Status
- Listed
- Listing
- IPO 2020
Open roles
Revolution Medicines in the Redwood City ecosystem
The Revolution Medicines office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series B and later8 investors entered at this stage
Casdin Capital- NINextech Invest
- SASchroder Adveq
Third Rock Ventures- BCBoxer Capital
Vivo Capital- TGThe Column Group
- UCUniversity of Illinois Urbana Champaign
Source: Dealroom Talent Intelligence.
Global footprint
Patents
86 active patent families included in this estimate.
A patent family groups patent filings for the same invention. Source: Dealroom · PatSnap.
Investments and acquisitions
Disclosed deals where Revolution Medicines was the backer or acquirer, 2018–2023. Toggle between venture rounds, M&A, or both. The map below is grouped by the target company's sector — the colored pill on each chip is the round type.
2 deals across Revolution Medicines's capital deployment.
Where the deals concentrate by sector, stage, and decade.
Revolution Medicines's portfolio, mapped.
See Revolution Medicines on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.
Tango's vopimetostat combination shows 82% response rate in pancreatic cancer at ESMO 2026
EMA committee backs Revolution Medicines' Rasonque for metastatic pancreatic cancer
Revolution Medicines wins FDA approval for Rasonque, the first drug to target the genetic driver of pancreatic cancer
